Catalent Analytical Team Member to be Published in Journal of Pharmaceutical Research
Released on: March 11, 2009, 12:36 am
Author: Dan Dunlop / Jennings
Research Triangle Park, N.C. - March 10, 2009 – Catalent
Pharma Solutions, a worldwide leading provider of advanced technologies
for pharmaceutical, biotechnology and consumer health companies, will
be featured in the upcoming April edition of Journal of Pharmaceutical
Research. Stephen P. Mayock, a member of Catalent’s analytical team,
was a major contributor to the article that conveys the present
challenges and future relevance of the science of USP 1 and 2
The article begins with the scientific origins of the dissolution test and discusses
the roles of dissolution in product development, consistent batch manufacture and
stability testing. It also reviews the ultimate role of dissolution testing where
the end results correlate to in vivo results. Other topics that are covered in the
article include the mechanical calibration versus performance testing, variability
and hydrodynamics of USP Apparatus 1 and 2 and new initiatives in the industry such
as quality by design, process analytical technology and design of experiment.
Mayock is the senior manager in Catalent’s Stability and Analytical Services Group.
Catalent’s analytical team is part of its Respiratory, Analytical and Biotechnology
group, with sites in the Research Triangle Park, N.C., San Diego C.A., and
Middleton, W.I. Mayock joins fellow authors Vivian Gray, Gregg Kelly, Min Xia, Chris
Butler and Saji Thomas. The article has been available online to subscribers since
Jan. 25, 2009, and the print version will be available in the April edition.
About the Journal of Pharmaceutical Research
Pharmaceutical Research, an official journal of the American Association of
Pharmaceutical Scientists, presents papers that describe innovative research
spanning the entire spectrum of drug discovery, development, evaluation, and
regulatory approval. Small drug molecules, biotechnology products including genes,
peptides, proteins and vaccines, and genetically engineered cells are an integral
part of papers published.
Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of
advanced dose form and packaging technologies, and development, manufacturing and
packaging services for pharmaceutical, biotechnology and consumer health companies
in nearly 100 countries. Catalent applies its local market expertise and technical
creativity to advance treatments, change markets and enhance patient outcomes.
Catalent employs approximately 9,500 at more than 30 facilities worldwide and
generates more than $1.8 billion of annual revenue. For more information, visit
Contact Details: Dan Dunlop, President & CEO
104-A North Elliott Road
Chapel Hill, NC 27514